Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1535
Abstract: TPN171 is a phosphodiesterase‐5 inhibitor. It is currently being developed in China to treat pulmonary arterial hypertension and erectile dysfunction (ED). This study aimed to compare the pharmacokinetics and safety of TPN171 across participants with… read more here.
Keywords: mild moderate; participants normal; tpn171; study ... See more keywords